A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial

The lower incidence of gynecologic adverse events and interventions with anastrozole and the early occurrence of these events provide further support for using anastrozole as the initial adjuvant treatment for early hormone receptor-positive breast cancer.